Cubist to acquire Trius, Optimer

|By:, SA News Editor

Cubist Pharmaceuticals (CBST) says it will acquire Trius Therapeutics (TSRX) for $13.50/ share plus CVRs worth $2/ share. (PR)

CBST will also buy Optimer Pharmaceuticals (OPTR) for $10.75/ share plus CVRs worth $5/ share tied to Dificid sales milestones. (PR)